Previous 10 | Next 10 |
home / stock / chsyf / chsyf news
SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreeme...
SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited (“CMS”), through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., a...
SHENZHEN, CHINA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Innovative drugs VALTOCO (Diazepam Nasal Spray),ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant H...
SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. T...
SHENZHEN, CHINA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cy...
SHENZHEN, CHINA, July 31, 2023 (GLOBE NEWSWIRE) -- Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited (“CMS” or the ...
SHENZHEN, CHINA, June 29, 2023 (GLOBE NEWSWIRE) -- CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global. Nearly 1600 Chinese companies were included in the selection pool, but only 88 companies, including CMS, were finally sel...
2023-06-18 07:05:00 ET Summary San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Cholesgen (Shanghai) formed a three-year collaboration with AstraZeneca to develop ...
SHENZHEN, CHINA, June 12, 2023 (GLOBE NEWSWIRE) -- CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China. The Product can meet current clinical needs for accessible and convenient treatment option of domestic epilepsy patients 6 year...
SHENZHEN, CHINA, May 30, 2023 (GLOBE NEWSWIRE) -- CMS is pleased to announce the NDA of Tildrakizumab Injection under the brand name of ILUMETRI, a monoclonal antibody specifically targeting the p19 subunit of IL-23, has been approved in China. ILUMETRI is indicated for the treatment of adu...
News, Short Squeeze, Breakout and More Instantly...
China Medical Sys Hldgs Company Name:
CHSYF Stock Symbol:
OTCMKTS Market:
SHENZHEN, CHINA, July 16, 2024 (GLOBE NEWSWIRE) -- In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in ...
SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging t...
SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue ® ) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients unde...